TrialMolecular pharmaceutics2025

Nonclinical and Clinical Assessments of an Optimized Tablet Formulation of the Novel HER2-Selective Tyrosine Kinase Inhibitor Zongertinib: Focus on Relative Bioavailability and Impact of Variation of Gastric pH.

Stefan Wölke et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.